Mabwell, a biopharmaceutical company known for its innovation-driven approach and fully integrated industry chain, has announced a major milestone: the Phase II clinical trial of its self-developed anti-IL-11 monoclonal antibody, 9MW3811, has dosed its first patient in China.

This makes 9MW3811 the world’s first IL-11-targeting drug candidate to enter clinical trials for pathological scarring.

The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring. The first patient received the treatment at Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine.

9MW3811 had previously completed Phase I trials in healthy subjects in Australia and China, which demonstrated a good safety profile and a half-life of more than one month.

Interleukin-11 (IL-11) is a cytokine known for its role in chronic inflammation and fibrosis across multiple organs.

Preclinical research shows that 9MW3811 has “demonstrated significant efficacy in various models such as pulmonary fibrosis, and has shown potential application value in fibrosis-related diseases such as hypertrophic scar and abnormal endometrial bleeding.” In human-derived keloid animal models, the antibody “can effectively alleviate the skin fibrosis process and reduce the volume of established scars.”